Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ: NKTR )

0.9078 +0.0073 (+0.81%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 505,654
Open 0.8917
Bid (Size) 0.8928 (10)
Ask (Size) 0.9074 (10)
Prev. Close 0.9005
Today's Range 0.8910 - 0.9119
52wk Range 0.4800 - 1.928
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. 
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
+52.62%
+52.62%
1 Month
-16.72%
-16.72%
3 Month
-21.74%
-21.74%
6 Month
-16.33%
-16.33%
1 Year
+74.58%
+74.58%

More News

Read More
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Sweet Nektar?
Via Talk Markets
Nektar Therapeutics Earnings Preview
Via Benzinga
Recap: Nektar Therapeutics Q3 Earnings
Via Benzinga
A Preview Of Nektar Therapeutics's Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Earnings Scheduled For March 4, 2024
Via Benzinga
Expert Ratings for Nektar Therapeutics
Via Benzinga
Nektar Therapeutics: Q1 Earnings Insights
Via Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The One-Minute Market Report - Saturday, Aug. 12
Via Talk Markets
Topics ETFs
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Nektar Therapeutics Stock Surging Today?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.